India, July 24 -- This week, the biotech sector was marked by FDA and EU approvals, strategic acquisitions, and a major workforce restructuring. Clinical trial updates delivered both breakthroughs and setbacks across oncology, obesity, and dermatology, underscoring the sector's volatility.
Let's break down the highlights driving investor sentiment.
Regulatory Approvals
AstraZeneca Gains EU Nod for Etcamah
AstraZeneca (AZN) secured European Union approval for Etcamah (camizestrant) plus CDK4/6 inhibitors in ER-positive, HER2-negative advanced breast cancer with ESR1 mutation. Phase 3 SERENA-6 data showed a 56% reduction in progression risk and median PFS of 16 months vs. 9.2 months for standard care.
AZN closed Thursday's trading (July ...